Guidance, NICE advice and quality standards in development | Guidance

Showing 141 to 150 of 443

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]	Technology appraisal guidance	TBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]	Technology appraisal guidance	TBC
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma	Interventional procedures guidance	TBC
Endoscopic submucosal dissection knives for the removal of gastrointestinal lesions	Health technology evaluation	TBC
Eneboparatide for treating chronic hypoparathyroidism [ID6532]	Technology appraisal guidance	TBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]	Technology appraisal guidance	15 June 2022
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6607]	Technology appraisal guidance	TBC
Ensitrelvir for treating COVID 19 [ID6231]	Technology appraisal guidance	TBC
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]	Technology appraisal guidance	TBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]	Technology appraisal guidance	25 February 2026